Navigation Links
GeneThera, Inc. Acquires Applied Genetics, S.A.
Date:1/25/2012

WESTMINSTER, Colo., Jan. 25, 2012 /PRNewswire/ -- GeneThera, Inc. (OTCQB: GTHR) announced today that it has acquired a majority ownership of Applied Genetics, a molecular diagnostic company based in Monterrey, Mexico. Applied Genetics is a molecular diagnostic company that focuses on commercializing molecular testing for Johne's disease in Mexico.

This acquisition is part of a broader strategy aimed at quickly initiating Applied Genetics revenue-generating operation.

Dr. Tony Milici, CEO of GeneThera and Interim President of Applied Genetics, commented on the news: "We are very pleased to have reached an agreement with the other shareholders of Applied Genetics to acquire a controlling interest in the company. We will continue our efforts to make GeneThera a leader in molecular diagnostic testing both in Mexico and South America."

Johne's disease is a global devastating and incurable disease of dairy cows, sheep, and goats caused by a bacterium called Mycobacterium Paratuberculosis sub. Avium, (MAP).   An overwhelming number of studies have shown that MAP is the causative agent of Crohn's disease in humans. Dairy products, contaminated with MAP, are the vehicles by which the infection spreads in the human intestine. Applied Genetics employs the use of GeneThera HerdCheck™ to test and control the spread of Johne's disease in Mexico.  HerdCheck™ is a proprietary molecular diagnostic system based on the use of high throughput robotics and Real time PCR.

About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES™ and Johne's disease management system, HERDCHECK™, designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES™ and HERDCHECK™ systems are designed for a host of individual diseases, the current priority being Johne's disease.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

For more information, contact Dr. Tony Milici at 720- 439-3011. http://www.genethera.net

GeneThera, Inc.


'/>"/>
SOURCE GeneThera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. [video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.nets 3-Minute Press Show
2. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
3. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
4. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
5. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
6. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
7. Advanced Instruments Acquires D & F Control Systems Inc.
8. Circassia Acquires North American and Japanese Rights to Dopexamine
9. CPA Acquires Renowned German Patent Research Specialist, SVPG
10. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
11. Affitech Acquires Pharmexas Diabody Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/9/2016)... Elevay is currently known as ... for high net worth professionals seeking travel for work ... world, there is still no substitute for a face-to-face ... your deal with a firm handshake. This is why ... of citizenship via investment programs like those offered by ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):